Our Work

In the News

PinneyAssociates is Seeking a Junior Associate

View Job Description»

Jack Henningfield and Sid Schnoll Submitted Comments on FDA Category 4 Labeling

View Henningfield PDF»

View Schnoll PDF»

Michael Hufford Presented New Research Showing Mobile Health Apps Could Support Novel OTC Switches

View PDF»

Pink Sheet interviewed Michael Hufford about nonprofit Harm Reduction Therapeutics’ goal of low-cost OTC naloxone

Pink Sheet»

Pinney Associates’ Scientific Abuse Potential Assessment of Kratom Finds Evidence of Public Health Benefit and Little Harm

View Press Release»

View 8-Factor Analysis»

More Smokers Trying to Quit – PinneyAssociates’ Analysis of National Health Interview Survey Data Confirms Increase in Attempts to Quit Smoking

View PDF»

PinneyAssociates Presents at FDA Public Meeting to Help Facilitate the Development of Abuse Deterrent Opioids

Learn what Ed Cone said about the FDA Abuse-Deterrent Guidance for Innovator and Generic Opioids

Watch Video »

PinneyAssociates Offers ALERRT® Methodology for In Vitro Assessment of Abuse-Deterrent Formulations

View PDF »


Can consumers self-select for appropriate use of an over-the-counter statin? The Self Evaluation of Lovastatin to Enhance Cholesterol Treatment Study

Brass EP, Vassil T, Replogle A, Hwang P, Rusche S, Shiffman S, Levine JG

Consumer understanding of prescription drug information: An illustration using an antidepressant medication.

Shiffman S, Gerlach KK, Sembower M, Rohay JM

Consumers appropriately self-treat based on labeling for over-the-counter hydrocortisone

Ellis CN, Pillitteri J, Kyle TK, Ertischek MD, Burton SL, Shiffman S

Ten years after the Rx-to-OTC switch of nicotine replacement therapy: what have we learned about the benefits and risks of non-prescription availability?

Shiffman S, Sweeney CT


The ALERRT® instrument: a quantitative measure of the effort required to compromise prescription opioid abuse-deterrent tablets.

Cone EJ, Buchhalter AR, Lindhardt K, Elhauge T, Dayno JM

Abuse potential assessment of novel opioid analgesic NKTR-181: implications for labeling and scheduling

Webster LR, Smith S, Silowsky J, Gogas K, Odinecs A, Eldon M, Abrouk N, Medve R, Henningfield JE, Buchhalter AR, Cone EJ, Fant RV, Schnoll S

An iterative model for in vitro laboratory assessment of tamper deterrent formulations

Cone EJ, Giordano J, Weingarten B

Do prescription monitoring programs impact state trends in opioid abuse/misuse?

Reifler LM, Droz D, Bailey JE, Schnoll S, Fant RV, Dart RC, Bucher Bartelson B

Epidemiology of stimulant misuse and abuse: implications for future epidemiologic and neuropharmacologic research

Gerlach KK, Dasgupta N, Schnoll S, Henningfield JE

Establishing “abuse-deterrence equivalence” for generic abuse-deterrent opioid formulations: A proposed development framework

Setnik B, Cone EJ

Extreme work requirement of EG-001, an abuse-deterrent, extended-release morphine product, as demonstrated with the ALERRT® Visual Analog Scales.

Cone EJ, Buchhalter AR, Lindhardt K, Elhauge T, Dayno JM

Nonmedical use of prescription ADHD stimulants and preexisting patterns of drug abuse

Sweeney CT, Sembower M, Ertischek MD, Shiffman S, Schnoll S

The new science of abuse-deterrence assessment of pharmaceutical products; FDA proposed guidance and Category 1 laboratory studies

Cone EJ, Buchhalter AR, Henningfield JE, Schnoll S


May 29-June 1 | Miami, Florida

Who will be there: Jack Henningfield, Daniel Wang

Pharmacodynamic and Cognitive Evaluation of CNS Drugs in Clinical Trials of Cannabis and Driving Impairment

June 10-12 | Boston, MA

Who will be there:

Improving the Benefit/Risk Ratio of Prescription Opioid Treatment: Can Buprenorphine Reduce the Adverse Effects of Prescription Opioid Abuse and Overdose?

June 9-14 | San Diego, CA

Who will be there: Jack Henningfield, Sidney Schnoll, Reggie Fant, August Buchhalter

Kratom and its Mitragynines in the Opioid Crisis: A Path to or Away from Opioids?

Pain Treatment with Buprenorphine as a Strategy to Reduce the Epidemic of Opioid Abuse and Overdose

Category 1 Assessment of Opioid Vaping: A Focus of FDA Advisory Committee Interest

Changing Career Opportunities for Trainees and Early Career Professionals in the Field of Drug Abuse Science

June 14-16 | Warsaw, Poland

Who will be there: Joe Gitchell, Annie Kleykamp, Robyn Gougelet

How to feel AND think about nicotine and those who use it

Rethinking nicotine across the lifespan: what about the older smoker?

Policy, Advocacy, and Practice Track: Regulation and Consumers

June 20-21 | Morristown, New Jersey

Who will be there: Joe Gitchell

The Future of Nicotine: Stalemated $%*#show or Stunning Policy Synchrony

June 21-24 | Minneapolis, MN

Who will be there: Daniel Wang

June 27 | Boston, MA

Who will be there: Sidney Schnoll

Safe Use and Prescribing of Opioid Medications: An In-Depth Look at the Strategies and Their Evaluation

June 28 | Webinar (1:00-2:30 PM)

Who will be there: Jack Henningfield, Reggie Fant

Register Here »

This webinar is the first of a 2-part series.